.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07A_BacterialVaccines.J07AH09_MeningococcusBMulticomponentVacc.MeningococcusBMulticomponentVacc .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07A_BacterialVaccines.J07AH09_MeningococcusBMulticomponentVacc.MeningococcusBMulticomponentVacc| name: | MeningococcusBMulticomponentVaccine |
| ATC code: | J07AH09 | route: | intramuscular |
| n-compartments | 0 |
Multicomponent meningococcus B vaccine (commonly known as 4CMenB) is a recombinant protein vaccine used to provide active immunization against Neisseria meningitidis group B (meningococcus B) infection. It is approved for use in many countries for the prevention of invasive meningococcal disease caused by serogroup B in infants, children, adolescents, and adults.
There are no published pharmacokinetic studies or pharmacokinetic parameter reports for the multicomponent meningococcus B vaccine (ATC J07AH09) in any demographic, as vaccines are generally not evaluated with classical pharmacokinetics due to their mechanism of action involving immunogenicity rather than systemic bioavailability of a single drug entity.